Bellicum Pharmaceuticals, Inc. (BLCM)

NASDAQ: BLCM · IEX Real-Time Price · USD
1.46
-0.09 (-5.81%)
May 20, 2022 4:30 PM EDT - Market closed
Market Cap12.57M
Revenue (ttm)6.20M
Net Income (ttm)-6.47M
Shares Out8.61M
EPS (ttm)-0.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,908
Open1.55
Previous Close1.55
Day's Range1.42 - 1.55
52-Week Range1.34 - 4.04
Beta1.45
AnalystsBuy
Price Target5.10 (+249.3%)
Earnings DateMay 16, 2022

About BLCM

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trial...

IndustryBiotechnology
IPO DateDec 18, 2014
CEORichard Fair
Employees7
Stock ExchangeNASDAQ
Ticker SymbolBLCM
Full Company Profile

Financial Performance

In 2021, BLCM's revenue was $6.20 million, an increase of 1,140.00% compared to the previous year's $500,000. Losses were -$9.71 million, 25.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 249.32% from the latest price.

Price Target
$5.1
(249.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement...

2 weeks ago - GlobeNewsWire

Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -

1 month ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference

HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...

3 months ago - GlobeNewsWire

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has rec...

5 months ago - GlobeNewsWire

Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exerci...

5 months ago - Benzinga

Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology -

6 months ago - GlobeNewsWire

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair,...

8 months ago - GlobeNewsWire

Why Is Bellicum Stock Moving Higher On Wednesday?

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and The University of Texas MD Anderson Cancer Center have announced a global option and license agreement for Bellicum's CaspaCIDe (inducible caspase-9, or i...

8 months ago - Benzinga

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD ...

8 months ago - GlobeNewsWire

Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity induce...

9 months ago - GlobeNewsWire

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered i...

10 months ago - GlobeNewsWire

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results...

1 year ago - GlobeNewsWire

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2

1 year ago - GlobeNewsWire

Bellicum to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT Management to host webcast and conference call on Tuesday, March 30, 2021 at 5 p.m. ET / 2 p.m. PT

1 year ago - GlobeNewsWire

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication...

1 year ago - GlobeNewsWire

Bellicum Reports FDA Lifted Clinical Hold on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that the U.S. Fo...

1 year ago - GlobeNewsWire

Bet on Rising P/E With These 5 Top-Ranked Stocks

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:BJLMNLQFINVCNXVIVO
1 year ago - Zacks Investment Research

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's Why

Bellicum Pharmaceuticals (BLCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603

HOUSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and a...

1 year ago - GlobeNewsWire

Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial

HOUSTON, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has been...

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals (BLCM) Upgraded to Buy: Here's What You Should Know

Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Rising P/E: An Ignored Trick to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:CAHFNFQLYS
1 year ago - Zacks Investment Research

Bellicum Reports Third Quarter 2020 Financial Results and Provides Operational Update

Strategic focus on clinical GoCAR-T ® programs with plans to initiate Phase 1/2 enrollment of BPX-601 in mCRPC and BPX-603 in HER2+ solid tumors by end of year

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering

HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of i...

1 year ago - GlobeNewsWire

Bellicum Pharmaceuticals to cut 79% of staff after disappointing trial data, stock suffering record plunge

Shares of Bellicum Pharmaceuticals Inc. plunged 35.1% in midday trading Friday, putting them on track for their biggest-ever one-day drop, after the clinical stage biopharmaceutical company said it was ...

1 year ago - Market Watch